# Cannabis Industry Stakeholders React to Trump DOJ’s Rescheduling Order, New Hearing > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-doj-rescheduling-order-industry-reactions/ > **Published:** 2026-04-24T10:09:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:03:38-04:00 > **Clinical Summary:** Explore cannabis DOJ rescheduling order impacts and industry reactions. Understand federal changes affecting medical cannabis access and research. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyRegulation[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)ResearchFederal Law Why This Matters Rescheduling proceedings directly impact [clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) access, research funding, and prescribing frameworks that affect thousands of patients currently using cannabis therapeutically. Changes in federal scheduling status could fundamentally alter how physicians can recommend, study, and integrate cannabis into evidence-based treatment protocols. Clinical Summary The DOJ’s rescheduling order and associated hearings represent continued federal movement toward potential cannabis rescheduling from Schedule I to Schedule III status. This regulatory shift would maintain federal oversight while potentially expanding research opportunities and reducing certain legal barriers for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs. The timeline and specific implementation details remain uncertain, with industry stakeholders expressing mixed reactions about pace and scope of proposed changes. Dr. Caplan’s Take “As a clinician, I’m watching this closely because rescheduling could finally enable the large-scale [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) we desperately need to establish dosing guidelines and safety profiles. The regulatory uncertainty, however, continues to complicate patient counseling and clinical decision-making.” Clinical Perspective 🧠 Physicians should stay informed about rescheduling developments as they may affect state medical cannabis programs and research opportunities. For now, [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) should continue following existing state frameworks while preparing for potential changes in federal research and prescribing guidelines. Patients should be counseled that regulatory changes may take months or years to impact actual clinical access. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Industry%20Stakeholders%20React%20to%20Trump%20DOJ%27s%20Rescheduling%20Order%2C%20New%20Hear...%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15823116/cannabis-industry-stakeholders-react-to-trump-dojs-rescheduling-order-new-hearing)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15823116/cannabis-industry-stakeholders-react-to-trump-dojs-rescheduling-order-new-hearing)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Industry%20Stakeholders%20React%20to%20Trump%20DOJ%27s%20Rescheduling%20Order%2C%20New%20Hear...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15823116/cannabis-industry-stakeholders-react-to-trump-dojs-rescheduling-order-new-hearing)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15823116/cannabis-industry-stakeholders-react-to-trump-dojs-rescheduling-order-new-hearing](https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15823116/cannabis-industry-stakeholders-react-to-trump-dojs-rescheduling-order-new-hearing) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DOJ Moves to Loosen Cannabis Restrictions, Signals Shift Toward Rescheduling](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) Learn about the DOJ's recent actions signaling a shift toward cannabis rescheduling and what it means for the industry. [Read More](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) What to Know About Trump’s Reclassification of [Medical Marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) – Time Magazine An overview of Trump's reclassification efforts and their potential impact on [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) policies. Explore Article [Trump Complains DOJ Is 'Slow-Walking' Marijuana Rescheduling, Four Months After He …](https://cedclinic.com/marijuana-rescheduling-delays-impact-clinical-practice/) Insights into Trump's criticism of DOJ's pace on marijuana rescheduling and the ongoing federal debate. [Learn More](https://cedclinic.com/marijuana-rescheduling-delays-impact-clinical-practice/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).